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Kazuhiko Nakagawa, MD, and Masahiro Fukuoka, MD¶¶
Purpose: To evaluate the combination chemotherapy using oral
antimetabolite S-1 plus cisplatin (SP) with concurrent thoracic
radiotherapy (RT) followed by the consolidation SP for locally
advanced non-small cell lung cancer.
Patients and Methods: Patients with stage III non-small cell lung
cancer, 20 to 74 years of age, and Eastern Cooperative Oncology
Group performance status 0 to 1 were eligible. The concurrent phase
consisted of full dose S-1 (orally at 40 mg/m2/dose twice daily, on
days 1–14) and cisplatin (60 mg/m2 on day 1) repeated every 4
weeks for two cycles with RT delivered beginning on day 1 (60
Gy/30 fractions over 6 weeks). After SP-RT, patients received an
additional two cycles of SP as the consolidation phase.
Results: Fifty-five patients were registered between November 2006
and December 2007. Of the 50 patients for efficacy analysis, the
median age was 64 years; male/female 40/10; Eastern Cooperative
Oncology Group performance status 0/1, 21/29; clinical stage IIIA/
IIIB 18/32; and adenocarcinoma/others 20/30. There were 42 clin-
ical responses including one complete response with an objective
response rate of 84% (95% confidence interval [CI], 71–93%). The
1- and 2-year overall survival rates were 88% (95% CI, 75–94%)
and 70% (95% CI, 55–81%), respectively. The median progression-
free survival was 20 months. Of the 54 patients for safety analysis,
common toxicities in the concurrent phase included grade 3/4
neutropenia (26%), thrombocytopenia (9%), and grade 3 esophagitis
(9%) and febrile neutropenia (9%). In one patient, grade 3 pneumo-
nitis was observed in the consolidation phase. There were two
treatment-related deaths caused by infection in the concurrent phase.
Conclusions: SP-RT showed a promising efficacy against locally
advanced NCSLC with acceptable toxicity.
Key Words: Concurrent chemoradiotherapy, Non-small cell lung
cancer, Phase II trial, S-1, Cisplatin.
(J Thorac Oncol. 2011;6: 2069–2075)
The standard treatment modality in patients with unresect-able stage III non-small cell lung cancer (NSCLC) is
concurrent chemoradiotherapy.1 Nevertheless, this combined
treatment is associated with greater acute toxicity, including
bone marrow2 suppression, pneumonitis, and esophagitis,2
compared with the sequential combination of chemotherapy
and radiotherapy (RT). About a decade ago, we developed a
concurrent chemoradiotherapy regimen using uracil-tegafur
(UFT, Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) plus
cisplatin (UP) with concurrent thoracic RT (2 Gy per fraction,
total 60 Gy) (UP-RT).3 The response rate and median sur-
vival time of locally advanced unresectable stage III (IIIA
20%, IIIB 80%) patients treated with the UP-RT were 80%
and 16.5 months, respectively, and these figures are similar to
those reported in other concurrent chemoradiotherapy tri-
als.4,5 Nevertheless, the incidence of leukopenia and esoph-
agitis of grade 3 or 4 was 16% and 3% of the patients,
respectively,3 and these figures are far lower than those of
other trials.
S-1 (TS-1, Taiho Pharmaceutical Co., Ltd) is a second-
generation oral anticancer agent based on uracil-tegafur,
which has a dihydropyrimidine dehydrogenase (DPD) inhib-
itory fluoropyrimidine. S-1 comprises tegafur (a 5-FU Pro-
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drug), 5-chloro-2, 4-dihydroxypyridine (an inhibitor of
DPD), and potassium oxonate (an inhibitor of phosphoribosyl
transferase), in a molar ratio of 1:0.4:1 and has been shown to
induce a comparable response to the other single agents for
metastatic NSCLC.6 Furthermore, combination chemother-
apy using S-1 plus cisplatin (SP) for advanced NSCLC has
been reported to show a response rate of 33 to 47% and a
median survival time of 11 to 16 months.7,8 Those data were
better than the usual response rate of 29 to 38% and the
median survival time of 8 to 13 months for the combination
chemotherapeutic regimens using UP,9,10 whereas the fre-
quency of severe hematological and nonhematological ad-
verse events induced by both UP and SP was lower than that
of other platinum-based combination regimens such as car-
boplatin plus paclitaxel (CP), cisplatin plus docetaxel, and so
on.11–13 In addition, West Japan Oncology Group (WJOG)
recently demonstrated that chemotherapy using S-1 plus car-
boplatin was noninferior in terms of overall survival (OS)
compared with CP in advanced NSCLC.14
The above-mentioned observations indicated that it
might be possible to use the same dose of SP as is used for
metastatic advanced NSCLC for the treatment of locally
advanced NSCLC with concurrent thoracic RT, similar to
UP-RT. If this is possible, SP and concurrent thoracic RT
(SP-RT) would be expected to provide several advantages
over UP-RT. First, SP could have stronger antitumor activity
for both locally advanced NSCLC and micrometastatic le-
sions than UP. Second, although both cisplatin and 5-FU have
been reported to have a radiosensitizing effect,15,16 the level
of the latter in the blood by SP could not only be maintained
at a higher level than by UP17,18 but also 5-chloro-2, 4-dihy-
droxypyridine in S-1 has been recently reported to have a
radiosensitizing effect as well as a strong DPD activity.19,20 A
single-institutional experience with SP-RT in 11 patients was
reported showing that all the patients had a partial response,
with acceptable hematological and nonhematological toxici-
ties. On the basis of these findings, the WJOG (formally,
West Japan Thoracic Oncology Group) conducted a multi-
institutional phase II trial to confirm the antitumor effects and
safety of SP-RT.
PATIENTS AND METHODS
Eligibility Criteria
The eligibility requirements for enrollment in this phase
II trial were cytologically or histologically confirmed, unre-
sectable stage III NSCLC, for which radical dose RT could be
prescribed. The staging was performed according to the 6th
edition of tumor, node, metastasis (TNM). All patients were
required to meet the following criteria: measurable disease;
an Eastern Cooperative Oncology Group performance status
of 0 or 1; a projected life expectancy of more than 3 months;
a leukocyte count of 4000/L; a platelet count of
100,000/L; a blood gas oxygen level of70 torr; a serum
bilirubin level below 1.5 mg/dL; serum glutamic oxaloacetic
transaminase/glutamic pyruvic transaminase levels of no
more than 100 IU/ml; a creatinine level of 1.2 mg/dL; and
a creatinine clearance level of 60 mL/min. Other eligibility
criteria included no prior treatment and an age75 years. All
eligible patients underwent computed tomography (CT) scans
of the thorax and upper abdomen and a radioisotope bone
scan. Patients who had malignant pleural effusion, malignant
pericardial effusion, a concomitant malignancy, or serious
concomitant diseases were excluded from the study. Written
informed consent was required from all patients, and the
protocol was approved by the institutional ethics committee
of each participating institute. All data were centrally moni-
tored by the WJOG datacenter. This study is registered with
the University Hospital Medical Information Network in
Japan (number 000001370).
Treatment Schedule
Chemotherapy with SP
S-1 (40 mg/m2/dose) in the form of 20 and 25 mg
capsules containing 20 and 25 mg of tegafur, respectively,
were taken orally twice a day after meals between days 1 and
14 as follows: in a patient with a body surface area (BSA)
1.25 m2, 40 mg twice daily; for those with BSA 1.25 m2,
but 1.5 m2, 50 mg twice daily; and BSA 1.5 m2, 60 mg
twice daily. Cisplatin (60 mg/m2) was administered as a
120-minute infusion on day 1. The patients were also
hydrated with 1000 to 2000 mL saline by infusion before
cisplatin was administered. An antiemetic agent was admin-
istered at the discretion of each patient’s physician.
The combination chemotherapy with SP was repeated
twice, with a 4-week interval, concurrently with thoracic RT
(SP-RT). At 2 to 4 weeks after the completion of the con-
current chemoradiotherapy, two further cycles of the same SP
regimen were administered as a consolidation chemotherapy
as shown in Figure 1.
A leukocyte count of 3000/L or greater and the entry
eligibility criteria regarding organ functions had to be satis-
fied for the patients to start the next cycle. If these criteria
were satisfied 4 weeks after day 1 of each cycle of chemo-
therapy, the next cycle was administered. The doses of S-1
were adjusted according to the degree of hematological and
nonhematological toxicity. The dose was reduced by one
level (20 mg day) in patients whose BSA was 1.25 m2 or
more if there was evidence of grade 4 hematologic toxicity or
grade 3 or more nonhematological toxicity during any cycle
FIGURE 1. Treatment schedule.
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of administration. If recovery from such toxicities was con-
firmed at a reduced dose, administration at the reduced dose
was continued. If a patient with a BSA less than 1.25 m2
experienced the above toxicities, then no further treatment
with S-1 was performed. If a rest period of more than 4 weeks
between two chemotherapy cycles of concurrent and consol-
idation phases was required or if the consolidation chemo-
therapy could not start within 6 weeks after SP-RT, then the
SP treatment was discontinued.
Radiotherapy
All patients were treated with a linear accelerator pho-
ton beam of 6 MV or more from day 1. The primary tumor
and involved nodal disease received 60 Gy in 2-Gy fractions
over a period of 6 weeks. In this protocol, both 2- and
3-dimensional (D) treatment planning systems were allowed.
The radiation doses were specified at the center of the target
volume. The doses were calculated assuming tissue homoge-
neity without correcting for lung tissues for both 2- and 3-D
treatment planning. Among the 54 patients assessable for
toxicity, 2- and 3-D treatment planning were performed for 7
and 47 patients, respectively. The initial 40 Gy/20 fractions
were delivered to clinical target volume 1 (CTV1), and the
final 20 Gy/10 fractions were delivered to a reduced volume
defined as clinical target volume 2 (CTV2). CTV1 included
the primary tumor, ipsilateral hilum, and mediastinal nodal
areas from the paratracheal (no. 2) to subcarinal lymph nodes
(no. 7). For the primary tumors and the involved lymph
nodes of 1 cm or more larger in the shortest diameter, a margin
of at least 0.5 cm was added. The contralateral hilum was not
included in CTV1. The supraclavicular areas were not treated
routinely but were treated when the supraclavicular nodes
were involved. CTV2 included only the primary tumor and
the involved lymph nodes, with a margin of 0.5 to 1 cm. The
spinal cord was excluded from the fields for CTV2 by
appropriate methods, such as the oblique opposing method.
The appropriate planning target volume margin and leaf
margin were added for CTV1 and CTV2. When grade 4
hematologic toxicity, grade 3 to 4 esophagitis or dermatitis,
pyrexia of 38°C, or a decrease in the partial pressure of
arterial oxygen of 10 torr or more were compared with that
before RT occurred, RT was interrupted. If a rest period of
more than 2 weeks was required, then the patient was with-
drawn from the study.
Evaluation of the Response and Toxicity
All registered patients, excluding those withdrawn from
the study, received the following evaluations. Chest x-rays,
complete blood cells, and blood chemistry studies were
repeated once a week during the treatment period. Thoracic
CT was performed every 1 or 2 months during the treatment
period. After the treatment, a thoracic CT was obtained every
6 months, and other imaging examinations were obtained
when recurrence was suspected. The response was evaluated
in accordance with the RECIST version 1.0 guidelines.21 In
this study, the results of the response which an investigator
determined were not used, and all responses were confirmed
by the board members of the independent response review.
During the evaluation of both the initial staging and the
antitumor effects, an extramural review was conducted. Only
patients whose initial clinical stage was judged to be stage
IIIA and IIIB and who were eligible for the study were
analyzed for the response to treatment. The toxicity for all
patients who received any treatment was assessed and graded
by using the National Cancer Institute Common Terminology
Criteria for Adverse Event version 3.
Statistical Analysis
The primary end point of this study was the objective
tumor response rate. On the basis of the assumption that a
response rate of higher than 80% would be expected from the
combined modality treatment, while a rate below 60% would
make a further investigation unnecessary, a sample size of 49
patients was required by the exact binomial test with a
one-sided alpha error of 0.05 and a beta error of 0.1. There-
fore, a total of 55 patients was the planned accrual size in
view of possibly including ineligible patients. For determin-
ing the response rate, the exact binomial confidence interval
(CI) was calculated. OS was defined as the time from regis-
tration until death from any cause. Progression-free survival
(PFS) was defined as the time between registration and
disease progression or death. The Kaplan-Meier method was
used to estimate OS and PFS curves. All statistical analyses
were done with SAS version 9.1.
RESULTS
Characteristics of Patients
Between November 2006 and December 2007, a total
of 55 patients were enrolled from 18 institutes. One patient
withdrew his consent and four patients were found to be
ineligible by the extramural review (one malignant effusion,
one carcinomatous lymphangitis, and 2 stage IV diseases).
Therefore, the efficacy analyses were performed for the 50
remaining eligible patients. Safety analyses were performed
for 54 patients who underwent SP-RT. Table 1 shows that
80% of the 50 eligible patients were male, with a mean age of
63 years (range, 40–74 years). Squamous cell carcinoma was
the most common histological diagnosis, including 48% of
the patients, and most patients had clinical stage IIIB disease
(IIIA versus IIIB; 36% versus 64%). The most frequently
classified TNM categories were T1-3N2 (36%), T1-3N3M0
(28%), and T4N0-1M0 (18%).
Adverse Events
The major adverse events (grade 3 and 4 toxicities) of
SP-RT are listed in Table 2. Among the hematologic toxici-
ties of the concurrent phase, grade 3 or higher leukopenia and
neutropenia was observed in 17 patients (32%) and 14 pa-
tients (26%), respectively. Five patients (9%) developed
grade 3 or higher thrombocytopenia. Among the nonhemato-
logic toxicities, grade 3 and 4 febrile neutropenia was ob-
served in four (7%) and one (2%) patient, respectively,
whereas grade 3 esophagitis occurred in 4 patients (7%).
Although no cases of severe pneumonitis occurred in the
concurrent phase, two patients had a treatment-related death:
one patient died of sepsis soon after the completion of the
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concurrent phase and the other patient died of pneumonia
after the recovery from the bone marrow suppression because
of that phase.
Thirty-nine (72%) of the 54 patients proceeded to
consolidation chemotherapy. As shown in Table 2, the fre-
quency of grade 3 or 4 in any major toxicity caused by
consolidation chemotherapy was lower than that in concur-
rent chemoradiotherapy, except for anemia and pneumonitis.
It was of note that no febrile neutropenia was observed.
Treatments Delivered to Eligible Patients
Tables 3 and 4 show RT and chemotherapy delivered to
50 eligible patients, respectively. Forty-six patients (92%)
completed two cycles of SP concurrent with thoracic RT of
60 Gy. Two patients refused further protocol treatment after
one cycle of chemotherapy because of adverse events. The
other two patients did not meet the criteria to start the second
cycle of SP because of prolonged neutropenia. Although 46
patients completed the concurrent phase of the SP-RT, seven
patients could not proceed to the consolidation phase because
of mainly prolonged hematological toxicity, and two patients
TABLE 1. Patient Characteristics
No. of eligible patients 50
Age, yrs
Mean (range) 63 (40–74)
Gender
Male 40 (80%)
Female 10 (20%)
ECOG PS
0 21 (42%)
1 29 (48%)
Smoking history
Absent 2 (4%)
Present 48 (96%)
Histology
Squamous cell carcinoma 24 (48%)
Adenocarcinoma 20 (40%)
Others 6 (12%)
cTNM
Stage IIIA 18 (36%)
T1-3N2 18 (36%)
Stage IIIB 32 (64%)
T1-3N3M0 14 (28%)
T4N0-1M0 9 (18%)
T4N2M0 7 (14%)
T4N3M0 2 (4%)
Location of primary site
Upper lobe 36 (72%)
Middle lobe 4 (8%)
Lower lobe 8 (16%)
Others 2 (4%)
ECOG, Eastern Cooperative Oncology Group; PS, performance status; TNM,
tumor, node, metastasis.
TABLE 2. Hematological and Nonhematological Major
Adverse Events
Toxicities
Concurrent
Chemoradiotherapy
(n  54)
Consolidation
Chemotherapy
(n  39)
Grade
Frequency of
3 or 4 (%)
Grade
Frequency of
3 or 4 (%)3 4 3 4
Hematological
Leukopenia 12 5 31.5 6 0 15.4
Neutropenia 10 4 25.9 4 0 10.3
Thrombocytopenia 1 4 9.3 4 0 10.3
Anemia 4 2 11.1 7 1 20.5
Nonhematological
Febrile neutropenia 4 1 9.3 0 0
Nausea 1 1 3.7 0 0
Vomiting 2 0 3.7 0 0
Anorexia 6 1 13.0 0 0
Creatinine 0 0 0 0
AST/ALT 1 1 3.7 0 0
Diarrhea 2 0 3.7 0 0
Stomatitis 1 0 1.9 0 0
Pneumonitis 0 0 1 0 2.6
Esophagitis 4 0 7.4 1 0 2.6
AST, aspartate transaminase; ALT, alanine aminotransferase.
TABLE 3. Radiation Delivered (N  50)
Radiation dose (Gy)
Median (range) 60.0 (28–60)
Average 58.4
Reasons for interruption, N (%)
Adverse events 7 (14.0)
Other 2 (4.0)
Rate of completion of treatment with 60 Gy, N (%) 47 (94.0)
TABLE 4. Chemotherapy Delivered (N  50)
N (%)
Concurrent chemotherapy
Chemotherapy cycles
1 50 (100)
2 46 (92.0)
Reasons for discontinuation
Adverse event 2 (4.0)
Patient decision 2 (4.0)
Reasons for not proceeding to
consolidation chemotherapy
Adverse event 8 (16.0)a
Other 1 (2.0)
Consolidation chemotherapy
Chemotherapy cycles
1 37 (74.0)
2 31 (62.0)
Reasons for discontinuation
Adverse event 5 (10.0)
Disease progression 1 (4.0)
Rate of completion of 4 cycles of
treatment (95% CI)
62% (47.2–75.3)
a Two treatment-related deaths were included after completion of concurrent
chemotherapy.
CI, confidence interval.
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were lost to treatment-related death. Of 37 patients, one and
five patients received only one cycle of the consolidation
chemotherapy because of disease progression and adverse
events, respectively. Thus, a total of 31 (62%) of the 50
eligible patients received all four cycles of SP chemotherapy.
Response
Of the 50 patients eligible for efficacy analysis, 42
patients had responses (84%; 95% CI, 71–93%; p  0.0001),
including 1 patient with a complete response, and 2 patients
with stable disease. Only one patient showed progressive
disease. Five patients were unevaluable for a response. There
were no differences in the response rate by histology (88% in
squamous cell carcinoma versus 81% in others, p  0.704 by
the exact binomial test).
Survival
The overall median follow-up time for the 29 patients
who were still alive as of January 2010 was 28 months
(range, 24–37 months). As shown in Figure 2, the median
PFS and OS was 20 months and not reached, respectively,
and the OS rates at 1 and 2 years were 88% (95% CI,
75–94%) and 70% (95% CI, 55–81%), respectively.
Sites of First Failures
With respect to the sites of first failure among the 28
(56%) patients with disease progression of the 50 eligible
patients, 19 (38%), 6 (21%), and 3 (6%) patients had distant
metastases, intrathoracic local diseases, and both, respec-
tively. Those nine occurred in the irradiated field. The fre-
quently observed initial distant metastases were observed in
bone in eight patients and in brain and lung in four each. Only
four patients (8%) developed a brain metastasis alone as the
initial failure site.
DISCUSSION
The purpose of concurrent chemoradiotherapy for
NSCLC patients with stage III disease is to achieve local
control, for which RT plays the main role, and also to
eradicate occult distant metastases by chemotherapy. For the
latter purpose, the development of regimens that can allow
administration of the systemic (full) doses of chemotherapy
during RT is necessary. Although the so-called “third gener-
ation” agents such as paclitaxel, vinorelbine, docetaxel, and
gemcitabine have been evaluated in several concurrent stud-
ies in combination with platinum compounds, a lower dose of
that agent plus the platinum compound has generally been
used due to toxicities. Therefore, induction chemotherapy
with sufficient systemic doses of the agents was considered a
potentially effective addition to the concurrent chemoradio-
therapy.22 Nevertheless, a recent randomized trial (CALGB
39801) showed that two cycles of induction chemotherapy
with full doses of CP did not provide a survival benefit over
concurrent chemoradiotherapy alone, using weekly CP at
lower doses.23 Furthermore, the randomized phase III trial
conducted by the Hoosier Oncology Group and U.S. Oncol-
ogy Group demonstrated that the addition of consolidation
chemotherapy using docetaxel after full-dose chemotherapy
using cisplatin plus etoposide with concurrent RT (PE-RT)
failed to achieve the primary end point of improved survival
compared with PE-RT alone.24 On the basis of these random-
ized trials, concurrent chemotherapy alone is recommended
for the treatment of locally advanced-NSCLC. However, the
optimal chemotherapy regimen remains to be determined.
In this study, SP-RT using systemic doses had the
advantage of eradicating occult distant metastases. In addi-
tion, 5-FU has been reported to have a radiosensitizing effect
in preclinical and clinical studies of various cancers, includ-
ing NSCLC,15,16 and S-1 is orally administered for 14 con-
secutive days in each course of chemotherapy, providing
long-term potential radiosensitization. The antitumor effects
of SP-RT might explain the high response rate of 82% and the
prolonged median PFS of 20 months, as well as the median
OS, which was not reached when follow-up time ranged from
24 to 37 months. Another SP-RT phase II trial with a similar
schedule and dose, which was conducted during almost the
same period as the present trial, also demonstrated a good
overall response rate of 88%, median PFS of 12 months, and
a median OS of 33 months, whereas the median follow-up
FIGURE 2. Overall survival ( ) and
progression-free survival ( ). Each tick
represents one patient who is alive with/
without recurrence. The bars represent
the 95% confidence intervals of the sur-
vival rate at 1 and 2 years after treatment.
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time was 25 months, ranging from 12 to 38 months.25 Nev-
ertheless, these data cannot be directly compared with our
data. In this trial, the extraordinarily good results may not be
only because of the chemotherapy regimen but also to the
high frequency of the primary site being within the upper
lobe. In completely resected NSCLC with N2 disease, the
5-year survival rate in patients with their primary site in the
upper lobe is well known to be significantly better than that
of patients with the primary tumor in the lower lobe.26 In
addition, the tumors in the upper lobe with upper mediastinal
nodal metastases are easier to treat with RT than the tumors
in the lower lobe in terms of the irradiation field.
Two additional cycles of the same chemotherapy after
concurrent chemoradiotherapy were called consolidation che-
motherapy in this trial. Although the original PE-RT regimen
used two additional cycles of the same PE after PE (two
cycles)-RT, the above-mentioned randomized trial did not
use consolidation PE in both control and experimental
groups.24 Similarly, the original mitomycin, vindesine plus
cisplatin (MVP)-RT regimen had the two additional cycles of
the same MVP5 after MVP (two cycles)-RT, whereas a recent
randomized trial used MVP (two cycles)-RT alone as a
control arm.27 The median OS of PE (2 cycles)-RT and MVP
(2 cycles)-RT was 23.2 and 23.7 months, respectively.24,27 In
addition, only 41% of the patients could complete four cycles
of MVP in the MVP-RT group of a recent WJTOG phase III
trial (WJTOG0105), which had a median OS of 20.5
months.28 In this trial, 62% of the patients completed four
cycles of SP despite a low frequency of severe toxicities,
whereas the WJOG phase III trial showed that the safest
regimen with concurrent RT was CP among MVP, CP, and
carboplatin plus CPT-11, although the completion rate of two
cycles in the consolidation chemotherapy of CP arm was only
50%.28 These observations suggest that a phase III trial is
necessary to clarify whether or not a total of four cycles of
chemotherapy in this setting provides a better result than two
cycles of chemoradiotherapy.
The irradiated dose of 60 Gy in 30 fractions with
concurrent chemotherapy is currently used in the majority of
institutes in Japan, whereas that of 66 Gy in 33 fractions in
combination with chemotherapy in the United States seems to
be the most common treatment regimen. Because PET/CT
scan and 3-D planning were not used in all patients, it would
therefore be interesting to elucidate whether or not the present
survival of such patients can be prolonged by these tech-
niques, including a total irradiated doses of 66 Gy.
Although the present treatment with SP-RT should be
acceptably safe in terms of the frequency of grade 3 and 4
adverse events, the treatment-related death of two patients
was observed. Therefore, it is necessary to keep in mind that
there is no totally safe regimen for concurrent chemoradio-
therapy. At present, the WJOG is conducting a randomized
phase II trial comparing SP-RT to combination chemotherapy
using cisplatin plus vinorelbine with concurrent RT.
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